| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Said A Al-Busafi, Ahmed Alwassief, Ali Madian, Hassan Atalla, Mohamed Alboraie, Ashraf Elbahrawy and Mohammed Eslam |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Said A Al-Busafi, Associate Professor, FRCP (C), MD, Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, PO Box: 35, Alkoudh.123, Muscat 123, Oman. busafis@squ.edu.om |
| Key Words |
Metabolic dysfunction-associated fatty liver disease; Gut dysbiosis, Gut-liver axis; Fecal microbiota transplantation; Microbiome-based diagnostics; Bile acid metabolism; Precision medicine |
| Core Tip |
The pathogenesis of metabolic dysfunction-associated fatty liver disease (MAFLD) is profoundly influenced by gut dysbiosis, a condition that exacerbates disease progression through mechanisms such as compromised intestinal barrier function, endotoxemia, and dysregulated bile acid metabolism. Understanding and addressing this issue is of utmost importance in the management of MAFLD. Advances in microbiome-based diagnostics, including machine learning models and microbial biomarkers, now provide non-invasive tools for early detection and risk stratification, enhancing clinical decision-making. The emergence of therapies targeting the gut-liver axis, such as probiotics, fecal microbiota transplantation, and farnesoid X receptor agonists, demonstrates significant potential in mitigating hepatic inflammation and restoring metabolic homeostasis. |
| Publish Date |
2025-08-27 09:21 |
| Citation |
Al-Busafi SA, Alwassief A, Madian A, Atalla H, Alboraie M, Elbahrawy A, Eslam M. Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies. World J Hepatol 2025; 17(8): 108730 |
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i8/108730.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i8.108730 |
